Caplin Point Laboratories (Mid Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Caplin Point Laboratories Limited |
|||
|
Price: ₹2,195.25 (-0.66%) | ||
| 52 Week Low: ₹1,225.00 52 Week High: ₹2,641.00 |
|||
| Market Capital: 15,125.73 Crore (Midcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Caplin Point Laboratories Share Price Target For 2025
- 1.1.1: Caplin Point Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Caplin Point Laboratories Share Price Target For 2026
- 1.2.1: Caplin Point Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Caplin Point Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Caplin Point Laboratories Brief Company Overview
- 4: Caplin Point Laboratories Financial Performance
- 4.0.1: Is Caplin Point Laboratories A Good Buy For Long Term?
Caplin Point Laboratories, a Mid Cap company in the Drug Manufacturers—Specialty & Generic Industry has delivered 681.9% returns in 5-year showing 17.8% quarterly revenue growth with 26.9% profit margin, making it a potential Multibagger.
To predict the Caplin Point Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Caplin Point Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Caplin Point Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Caplin Point Laboratories shares in 2025, see the table below.
Caplin Point Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 2463.65 (+12.22%) | Price Action: 10 Jan 2025 High |
| 2025 Target 2 | 2438.0 (+11.05%) | Price Action: 23 Dec 2024 High |
| 2025 Target 1 | 2408.0 (+9.69%) | Price Action: 20 Dec 2024 High |
| Current Price | 2195.25 | Caplin Point Laboratories's share price as of 21 Jan 2025 |
| Stop Loss 1 | 2076.05 (-5.43%) | Price Action: 28 Nov 2024 Low |
| Stop Loss 2 | 2049.9 (-6.63%) | Price Action: 03 Oct 2024 High |
| Stop Loss 3 | 2024.74 (-7.77%) | Price Action: 11 Sep 2024 High |
Short-Term Technical Outlook
Current Technical Position: Caplin Point Laboratories is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 50-day moving average at ₹2292.61 serves as the nearest technical reference point.
Historical Returns: 3-month: +7.85% | 6-month: +39.65% | 1-year: +52.06%
Caplin Point Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Caplin Point Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Caplin Point Laboratories shares in 2026, see the table below.
Caplin Point Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 3676.35 (+67.45%) | Fibonacci Extension Level 150.00% |
| 2026 Target 2 | 3574.52 (+62.82%) | Price Action: Chart |
| 2026 Target 1 | 3539.13 (+61.21%) | Fibonacci Extension Level 64.90% |
| Current Price | 2195.25 | Caplin Point Laboratories's share price as of 21 Jan 2025 |
| Stop Loss 1 | 1888.0 (-14%) | Price Action: 23 Sep 2024 Low |
| Stop Loss 2 | 1867.59 (-14.93%) | Price Action: Sep 2024 Low |
| Stop Loss 3 | 1841.55 (-16.12%) | Price Action: 28 Oct 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Caplin Point Laboratories is currently trading at 68.5% of its 52-week range (₹1225 - ₹2641).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +52.06% | 3-year: +179.85% | 5-year: +681.9%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Caplin Point Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹2,195.25 | ||
| 2025 | ₹3,770.77 | +71.76% | ₹3,827.33 |
| 2026 | ₹5,913.04 | +56.81% | ₹6,001.74 |
| 2027 | ₹8,993.72 | +52.09% | ₹9,128.63 |
| 2028 | ₹13,293.90 | +47.81% | ₹13,493.31 |
| 2029 | ₹20,761.10 | +56.17% | ₹21,072.52 |
| 2030 | ₹28,559.16 | +37.56% | ₹28,987.55 |
| 2031 | ₹38,302.06 | +34.11% | ₹38,876.59 |
| 2032 | ₹47,830.48 | +24.87% | ₹48,547.94 |
| 2033 | ₹63,443.92 | +32.64% | ₹64,395.58 |
| 2034 | ₹87,677.74 | +38.19% | ₹88,992.91 |
| 2035 | ₹109,575.07 | +24.97% | ₹111,218.70 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Caplin Point Laboratories Brief Company Overview
Caplin Point Laboratories Limited: Driving Healthcare with Quality Pharma Caplin Point Laboratories, established in 1990, is a leading Indian pharmaceutical company with an impressive history and global presence. Headquartered in Chennai, the company specializes in...
developing, manufacturing, and distributing a wide range of generic and branded pharmaceutical formulations. Caplin's diverse product portfolio includes liquid and lyophilized vials, pre-filled syringes, ophthalmic droppers, pre-mix bags, and various oral dosage forms such as tablets, capsules, and syrups. The company's commitment to innovation is evident in its extensive product line, catering to diverse therapeutic areas. The company has a solid reputation in the industry for delivering high-quality, affordable medications. Its adherence to strict regulatory standards ensures the safety and efficacy of its products, establishing Caplin as a trusted name in the healthcare sector.Caplin Point Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 15,125.73 Crore | Market valuation of Caplin Point Laboratories's shares. |
| Revenue (TTM) | 1,832.79 Crore | Total revenue generated by Caplin Point Laboratories over the past twelve months. |
| Net Income (TTM) | +493.56 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +30.63% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +26.92% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+17.8% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+13.9% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
0.09 | Company's total debt divided by total shareholder equity. |
| Total Debt | 2.43 Crore | Sum of Caplin Point Laboratories's current & long-term financial obligations. |
| Total Cash | 826.62 Crore | Total amount of liquid funds available to Caplin Point Laboratories. |
| Beta | 0.39 | Beta is less than 1 indicating that the Caplin Point Laboratories's price is less volatile than the market. |
Is Caplin Point Laboratories A Good Buy For Long Term?
Caplin Point Laboratories, a mid-cap stock with a market capitalization of ₹15,125.73 crore, shows strong financial health. Boasting a robust profit margin of 26.92% and impressive revenue growth of 17.8% QoQ (Q2 2024-25), the company’s ₹826.62 crore cash balance significantly outweighs its ₹2.43 crore debt. While past returns have been exceptionally high (91.49% in the last 12 months, 414.27% over 5 years), this level of growth may not be sustainable. Therefore, while the company presents a compelling case, it's considered an average buy for the long term, acknowledging the inherent risk associated with such high past performance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
